Abstract

Autoimmune diseases are chronic, often debilitating conditions characterized by immune system dysregulation and self-tissue destruction. Conventional treatments provide symptomatic relief but rarely alter disease progression. Recent advances in stem cell therapy—particularly hematopoietic stem cell transplantation (HSCT) and mesenchymal stem cell (MSC) therapy—offer promising avenues for immune system reprogramming and long-term remission. This review explores the current state of stem cell-based interventions for autoimmune diseases, underlying mechanisms, clinical outcomes, and future prospects.

1. Introduction

Autoimmune diseases affect approximately 5–10% of the global population and include a wide spectrum of disorders such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), type 1 diabetes (T1D), and inflammatory bowel disease (IBD). These diseases are characterized by loss of immunological tolerance to self-antigens, leading to chronic inflammation and tissue destruction. Current pharmacological treatments, including corticosteroids and immunosuppressants, often fail to induce durable remission and are associated with significant adverse effects. Stem cell therapy has emerged as a novel, potentially curative strategy by enabling immune system reset or modulation.

2. Types of Stem Cells Used in Autoimmune Therapy

2.1 Hematopoietic Stem Cells (HSCs)

HSCs are multipotent stem cells capable of regenerating the entire hematopoietic and immune system. Autologous HSCT (AHSCT) is the most studied form of stem cell therapy for autoimmune diseases. It involves immunoablation followed by reinfusion of the patient’s own HSCs, leading to immune reconstitution and tolerance induction.

2.2 Mesenchymal Stem Cells (MSCs)

MSCs are multipotent stromal cells derived from bone marrow, adipose tissue, or umbilical cord. They exhibit strong immunomodulatory and anti-inflammatory properties. Unlike HSCT, MSC therapy does not require high-dose conditioning and can be administered intravenously without extensive pre-treatment.

2.3 Induced Pluripotent Stem Cells (iPSCs)

Though still largely experimental, iPSCs offer a theoretically unlimited source of patient-specific cells. Their potential for differentiation into immune and tissue-specific cells opens novel pathways for autoimmune intervention, though safety concerns such as tumorigenesis remain.

3. Mechanisms of Action

Stem cell therapies target autoimmune pathology through several key mechanisms:

• Immune Resetting: HSCT reboots the immune system, potentially erasing autoreactive clones.

• Immunomodulation: MSCs suppress T-cell proliferation, induce regulatory T cells (Tregs), and modulate dendritic cell function.

• Anti-Inflammatory Effects: Both HSCT and MSCs reduce levels of pro-inflammatory cytokines (e.g., TNF-α, IL-6) and promote anti-inflammatory cytokine production (e.g., IL-10).

• Tissue Repair: MSCs support regeneration of damaged tissues through paracrine signaling and differentiation.

4. Clinical Applications in Autoimmune Diseases

4.1 Multiple Sclerosis (MS)

Autologous HSCT has shown significant success in aggressive relapsing-remitting MS, with improved progression-free survival and reduced relapse rates. MSCs have demonstrated neuroprotective effects in early trials.

4.2 Systemic Lupus Erythematosus (SLE)

MSC therapy has resulted in reduced disease activity and improved renal function in lupus nephritis patients. AHSCT is considered in refractory cases.

4.3 Rheumatoid Arthritis (RA)

MSC therapy has been associated with decreased joint inflammation and improved functional outcomes, though large-scale trials are ongoing.

4.4 Type 1 Diabetes (T1D)

Stem cell therapy aims to preserve or regenerate insulin-producing beta cells. Early studies with MSCs and HSCs show potential to delay disease progression and reduce insulin dependence.

4.5 Inflammatory Bowel Disease (IBD)

MSCs have demonstrated efficacy in refractor